New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
09:23 EDTGRFS, HALO, CRIS, ING, AMGN, SINA, EXAS, PRAN, MNKD, LULUOn The Fly: Pre-market Movers
HIGHER: Lululemon (LULU), up 3% following upgrade at Wedbush... SINA (SINA), up 3.5% after upgraded at Pacific Crest... Grifols (GRFS), up 2.5% after announcing 7-year agreement with Japanese Red Cross... Exact Sciences (EXAS), up 3.6% after Barron's says shares could rise 50%... Curis (CRIS), up 11% after announcing removal of FDA partial clinical hold on CUDC-427... Halozyme (HALO), up 9% after announcing that trial of Hylenex recombinant met primary endpoint... ING (ING), up 4.5% after paying EUR1.23B to Dutch State... Amgen (AMGN), up 2% after AMG 145 reduced LDL cholesterol in statin intolerant patients... LOWER: Prana (PRAN), down 66% after Alzheimer's study doesn't hit targets... MannKind (MNKD), down 5.6% after downgraded at Piper Jaffray.
News For LULU;MNKD;PRAN;EXAS;SINA;AMGN;ING;CRIS;HALO;GRFS From The Last 14 Days
Check below for free stories on LULU;MNKD;PRAN;EXAS;SINA;AMGN;ING;CRIS;HALO;GRFS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 8, 2014
07:15 EDTAMGNIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
06:49 EDTAMGNAmgen shares to trend higher, price target to $150 at RBC Capital
RBC expects shares of Amgen to trend higher due to evolving sentiment around the 2015 pipeline and low multiple. Some investors want a break-up of the company to increase shareholder value but the analyst does not expect it to occur given the concentrated portfolio, tax reasons, and a commercial infrastructure that can not be split off. Shares are Outperform rated with a $150 price target, raised from $135.
06:42 EDTLULUlululemon expected to report sharply lower profit, WSJ reports
lululemon is expected to report a sharply lower profit, with analysts expecting a profit of $42.7M in the latest quarter, reports the Wall Street Journal. Investors will be watching for signs the self-inflicted problems are getting resolved after executives said overhauling the company's process will take about 18 months. Reference Link
September 5, 2014
16:25 EDTPRANOn The Fly: Closing Wrap
Subscribe for More Information
15:21 EDTLULULululemon Athletica September volatility elevated into Q2
Subscribe for More Information
10:28 EDTPRANHigh option volume stocks
Subscribe for More Information
10:05 EDTINGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:49 EDTLULUlululemon challenges persisted in Q2, says Canaccord
Canaccord said the product assortment at lululemon remains stale and the firm sees traffic, product flow, fashion quotient and conversion challenges persisting in Q2. The firm believes the brand remains relevant and has long-term growth opportunities but there are likely to be more fits and starts in the interim. Canaccord keeps its Hold rating and $42 price target on shares of lululemon.
07:19 EDTINGING Groep upgraded to Overweight from Equal Weight at Barclays
07:18 EDTINGRegulators drafting flexible 'bail in' bond deal for large banks, Reuters says
Subscribe for More Information
06:34 EDTLULUlululemon estimates lowered ahead of Q2 report at Barclays
Subscribe for More Information
September 4, 2014
18:50 EDTPRANPrana up 9.8% in after hours trading after receiving FDA orphan designation
Subscribe for More Information
18:06 EDTPRANPrana granted orphan status for treatment of Huntington disease
The FDA posted on its website that Prana Biotechnology has been granted orphan status for its treatment of Huntington's disease. Reference Link
13:05 EDTLULULululemon Athletica September volatility elevated into Q2
Lululemon Athletica September 12 weekly call option implied volatility is at 72, September is at 56, October is at 46, January is at 37; compared to its 26-week average of 38 according to Track Data, suggesting larger September price movement into the expected release of Q2 on September 11.
September 3, 2014
08:31 EDTHALOHalozyme's PEGPH20 program receives fast track designation
Subscribe for More Information
05:59 EDTSINA SINA implied volatility of 35 at lower end of index mean range
September 2, 2014
16:35 EDTINGVoya Financial announces secondary common stock offering of 30M shares by ING
Voya Financial (VOYA) announced that ING Group (ING) has entered into an agreement with a syndicate of underwriters to sell Voya Financial common stock in an underwritten public offering. Voya Financial will not be issuing or selling common stock, and will not receive any proceeds from the offering. In connection with the public offering, Voya Financial has entered into a share repurchase agreement with ING Group pursuant to which Voya Financial will repurchase directly from ING Group shares of Voya Financial common stock for an aggregate purchase price of $300M. The per-share purchase price to be paid by Voya Financial in the direct share repurchase will be equal to the per-share purchase price paid by the underwriters in the public offering. The direct share repurchase is subject to a number of conditions, including the successful completion of the public offering. Voya Financial expects to fund the direct share repurchase using cash on hand. The total number of shares of Voya Financial common stock to be sold by ING Group, including both the underwritten public offering and shares repurchased by Voya Financial, is expected to equal 30M shares. Completion of the public offering and the direct share repurchase is estimated to reduce ING Group's stake in Voya Financial from approximately 43% to approximately 32%.
08:21 EDTAMGNAmgen submitts MAA to EMA for evolocumab
Subscribe for More Information
08:20 EDTAMGNAmgen submits application to EMA for talimogene laherparepvec
Subscribe for More Information
08:01 EDTAMGNAmgen price target raised to $153 from $140 at Leerink
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use